Back to news

Hims & Hers Health Shares Fall as Investors Weigh Recent GLP-1 Expansion and Upcoming Earnings

Investivoq PriceTracker

Hims & Hers Health (HIMS) is down 7.3% today. Here is some analysis on what might have caused this price movement.

Analysis: A clear single-day negative catalyst is not obvious, so the move appears tied to positioning ahead of the company’s November 9, 2026 earnings report and ongoing debate about profitability in its weight-loss business. This could also be a sell-the-news reaction after the recent expansion of access to branded Lilly obesity medicines, as investors weigh whether stronger demand will come with lower margins or higher operating costs.

Details:

  • The company recently announced an agreement that lets eligible patients access Lilly’s FDA-approved obesity medicines, including Zepbound and Foundayo, through the Hims & Hers platform.
  • Market data shows the stock trading lower this morning, while the company’s next earnings release is scheduled for November 9, 2026, keeping investor focus on near-term guidance and execution.
  • In its most recent quarterly report, the company posted strong revenue and subscriber growth but also reported a net loss and cash used in operations, reinforcing questions about the cost of expansion.
  • The company’s recent filings and prior updates show continued investment in international expansion, AI tools, and new categories, which may support growth over time but can also pressure sentiment when investors are looking for clearer profit traction.

    • Sources:

    Hims & Hers Investor Relations, Yahoo Finance, SEC

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $HIMS Insider Trading Activity

    HIMS Insider Trades

    $HIMS insiders have traded $HIMS stock on the open market 25 times in the past 6 months. Of those trades, 1 have been purchases and 24 have been sales.

    Here’s a breakdown of recent trading of $HIMS stock by insiders over the last 6 months:

    • OLUYEMI OKUPE (Chief Financial Officer) has made 0 purchases and 10 sales selling 153,772 shares for an estimated $4,942,061.
    • SOLEIL BOUGHTON (Chief Legal Officer) has made 0 purchases and 6 sales selling 45,189 shares for an estimated $1,260,593.
    • DAVID B WELLS purchased 48,400 shares for an estimated $1,172,974
    • MOHAMED ELSHENAWY (CTO) has made 0 purchases and 2 sales selling 37,994 shares for an estimated $1,172,074.
    • MICHAEL CHI (Chief Operating Officer) has made 0 purchases and 2 sales selling 28,054 shares for an estimated $840,077.
    • PATRICK HARRISON CARROLL (Chief Medical Officer) sold 23,726 shares for an estimated $830,410
    • DEBORAH M. AUTOR (Chief Policy Officer) sold 16,773 shares for an estimated $467,128
    • IRENE BECKLUND (PAO) has made 0 purchases and 2 sales selling 12,063 shares for an estimated $370,518.

    To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

    EARLY ACCESS
    Receive HIMS Data Alerts
    Real-time alerts on filings, insider trades, and market signals — before everyone else.
    Get Alerts →

    $HIMS Hedge Fund Activity

    We have seen 259 institutional investors add shares of $HIMS stock to their portfolio, and 248 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • DEFIANCE ETFS, LLC removed 7,424,258 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $257,399,024
    • DIVISADERO STREET CAPITAL MANAGEMENT, LP added 5,539,672 shares (+1179.1%) to their portfolio in Q2 2026, for an estimated $192,060,428
    • JPMORGAN CHASE & CO added 4,766,781 shares (+inf%) to their portfolio in Q2 2026, for an estimated $165,264,297
    • FMR LLC added 4,230,022 shares (+4535.2%) to their portfolio in Q2 2026, for an estimated $146,654,862
    • MARSHALL WACE, LLP added 3,493,540 shares (+482.4%) to their portfolio in Q2 2026, for an estimated $121,121,031
    • GOLDMAN SACHS GROUP INC added 2,719,170 shares (+110.8%) to their portfolio in Q2 2026, for an estimated $94,273,623
    • SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 2,453,787 shares (+inf%) to their portfolio in Q2 2026, for an estimated $85,072,795

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    $HIMS Price Targets

    Multiple analysts have issued price targets for $HIMS recently. We have seen 4 analysts offer price targets for $HIMS in the last 6 months, with a median target of $38.0.

    Here are some recent targets:

    • Allen Lutz from B of A Securities set a target price of $37.0 on 07/09/2026
    • Maria Ripps from Canaccord Genuity set a target price of $40.0 on 07/01/2026
    • Glen Santangelo from Barclays set a target price of $39.0 on 06/18/2026
    • Jailendra Singh from Truist Securities set a target price of $23.0 on 05/22/2026

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.